

From: Michael Perfetto </O=ONETEAM/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS /CN=MPERFETTO>
To: Kelly Smith; Rachelle Galant
CC: John LaRocca; John Duff; Nancy Baran
Sent: 5/6/2011 3:54:21 PM
Subject: RE: Meeting Today Regarding QK Healthcare Oxy Ordering Pattern

Yes – we have engaged Dendrite and we have an internal team that I'd like you to be involved with....

Additionally, marketing has improved system that reviews business trends by customer.

But saying all that.... We welcome your involvement and that is why we want have asked for your input.

Rachel can brief you on QK.

Once again, thank you for your support.

Michael Perfetto
VP, Sales and Marketing



Actavis
60 Columbia Rd. Bldg B t +1 908-868-9778 @ mperfetto@actavis.com
Morristown, NJ 07960 United States f 607-724-0322 w www.actavis.com
Internal VoIP number

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Kelly Smith
Sent: Friday, May 06, 2011 11:44 AM
To: Rachelle Galant
Cc: Michael Perfetto; John LaRocca; John Duff
Subject: Meeting Today Regarding QK Healthcare Oxy Ordering Pattern

Rachelle,

In regards to this morning's meeting, discussion of QK Healthcare's Oxy Ordering Pattern. Per your request, I am available to call the vendor on Monday morning. We need to make sure that all questions to the vendor, are as discussed in today's meeting. I would like to receive information regarding their customer base, reasons for increased volume, payment pattern and type. We need to make them aware in a registered mail, **written format**, AFTER, the conference call that we have a "suspicious order" program and that all orders of a suspicious nature are reported to the DEA, per our obligation to do so, per Federal Law. As far, as the DEA is concerned, if it isn't written down, it did not happen.

Mike, per our last discussion, you had hired a vendor to develop an enhanced "suspicious order" program. Are they onboard, right now? Further, I believe that before we bring these companies onboard we should do increased "due diligence". Sales and Marketing may not be the best outlet for this. Perhaps Security and Legal should be involved. As you know, many illegitimate companies are looking for new suppliers due to recent DEA scrutiny and closure of previous suppliers, due to these sorts of problems.

Regards,



Highly Confidential



Acquired_Actavis_01317298

P-02470 _ 00001

Kelly

Kelly Smith
Director



Actavis
60 Columbia Rd. Bldg B t +1 973-889-6970 @ ksmith@actavis.com
Morristown, NJ 07960 United States w www.actavis.com
Internal VoIP number t 125-6970

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

From: Rachelle Galant
Sent: Friday, May 06, 2011 8:58 AM
To: Kelly Smith
Subject: available this afternoon for a meeting?

Hi Kelly –
I hope you are feeling better. I was just checking your availability this afternoon to discuss QK Healthcare's ordering pattern on the Oxy IR tabs.
Please let me know if you are in the office and have time to schedule a quick call with them.
Many thanks,
Rachelle

Rachelle Galant
Senior Product Manager



Actavis
60 Columbia Rd. Bldg B t +1 973-993-4527 @ RGalant@actavis.com
Morristown, NJ 07960 United States w www.actavis.com
Internal VoIP number t 125-4527

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphold strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

Highly Confidential

Acquired_Actavis_01317299

P-02470 _ 00002